Related Experiment Video
Updated: Jan 3, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.9K
Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial
Thomas J Pugh1, Seungtaek Choi2, Graciela M Nogueras-Gonzalaez3
1University of Colorado Hospital, Aurora, CO, USA.
International Journal of Particle Therapy
|November 28, 2019
Summary
Proton beam therapy (PBT) for prostate cancer shows excellent survival and biochemical control rates. This treatment offers minimal high-grade toxicity and a modest impact on quality of life (QOL).
Area of Science:
- Oncology
- Radiation Oncology
- Prostate Cancer Treatment
Background:
- Proton beam therapy (PBT) is an advanced radiation technique for prostate cancer.
- Assessing long-term outcomes, toxicity, and quality of life (QOL) is crucial for PBT evaluation.
Purpose of the Study:
- To evaluate prostate cancer outcomes, toxicity profiles, and QOL in patients treated with PBT.
- To provide data on the efficacy and safety of contemporary PBT for prostate cancer.
Main Methods:
- A prospective trial involving 423 men with prostate cancer treated with PBT (75.6-78 Gy RBE).
- Biochemical failure assessed by the Phoenix definition; toxicity by Modified Radiation Therapy Oncology Group criteria.
- Quality of life (QOL) measured using Expanded Prostate Cancer Index Composite questionnaires.
Main Results:
- Excellent 5.2-year survival (overall 99.8%, disease-specific 100%) and low biochemical failure rate (5.2%).
- Low rates of acute and late toxicity: no acute grade ≥3 GI/GU toxicity; 2 late grade 3 GI toxicities.
- Modest, clinically significant decrement in bowel QOL observed; urinary, sexual, and hormonal QOL remained stable.
Conclusions:
- Contemporary PBT achieves excellent biochemical control and survival for prostate cancer.
- PBT demonstrates a minimal risk of severe toxicity and a manageable impact on QOL.
- Further comparative studies of PBT versus other prostate cancer treatments are warranted.
